Despite pivotal trials of the disease-modifying agents interferon beta and glatiramer acetate, worldwide approval by licensing agencies, and a growing trend to treat all patients with early multiple sclerosis, controversy still exists about who and when to treat. 1,2 When a person presents to a neurologist for evaluation of a fi rst event (clinically isolated syndrome) suggestive of multiple sc...